chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Post vax, the pt developed a low grade fever, chills, myalgias, decreased appetite, and mild frontal headache.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On an unknown date the patient was vaccinated with GARDASIL 9 for prophylaxis.  On an unknown date the patient experienced inappropriate schedule of drug administration and no adverse event. The outcome of inappropriate schedule of drug administration and no adverse event is unknown. The reporter considered inappropriate schedule of drug administration and no adverse event to be not related to GARDASIL 9.
headache; Burning in rib cartilage swellings (fromTietze Syndrome); nauseas; vomiting; Low back pain; This is a spontaneous report from a contactable consumer, the patient. A 43-years-old non-pregnant female patient received a single dose of BNT162B2 (Pfizer BioNTech Covid 19 mRNA Vaccine; Lot/batch no: EN6208) via an unspecified route of administration on 15Mar2021, at 14:30 (at the age of 43-year-old) for COVID-19 immunisation. Medical history of the patient included hemochromatosis, CPPD (Calcium pyrophosphate dihydrate crystal deposition disease), Tietze Syndrome, Reynaud's syndrome and autoimmune disorder. The patient was not pregnant at the time of vaccination. The patient was allergic to medications, food or other products. Concomitant medications included magnesium, lysine and multivitamin. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 16Mar2021, at 15:00, the patient experienced burning in rib cartilage swellings (from Tietze Syndrome). She also had low back pain, nauseas, headache and vomiting. No therapeutic measures were taken as a result of those events. The clinical outcome of the events burning in rib cartilage swellings (from Tietze Syndrome), low back pain, nauseas, headache and vomiting was not recovered.
Upon receiving Pfizer Bivalent, it was improperly stored in the freezer. This vaccine should have been stored in the refrigerator. Due to the incorrect storage patient received vaccine that was expired. NO ISSUES REPORTED
a tightness on both ankles; legs swell up, both of her legs at the ankle level; legs swell up, both of her legs at the ankle level; This is a spontaneous report from a contactable consumer (patient). A 68-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number and expiration was not reported, as she does not have vaccination card handy), via an unspecified route of administration, administered in arm left on 26Feb2021 as single dose for covid-19 immunization. The patient took COVID-19 Vaccine because her husband insisted. The patient medical history and concomitant medications were not reported. No other products and no investigation assessment done. The patient had no other vaccines on the same day as her COVID vaccine. The patient was calling regarding the COVID-19 Vaccine shot. The patient was trying to find out if something she was experiencing, was a side effect of the product. The patient stated that her legs swell up, both of her legs at the ankle level on an unspecified date in 2021 and that had never happened to her before. The patient received her vaccine on 26Feb2021, and she did not know the exact day the swelling started, but she noticed it shortly after getting the shot. The patient confirmed the swelling was ongoing, she was concerned because it had not gone away. When queried regarding outcome, the patient stated that it was still about the same, it was a tightness on both ankles (start date: unspecified) and they were swollen and she thought at first that maybe it was because she walked so far from the parking lot to the facility to get the shot, but it had not receded at this point, so she did not know what was going on, because she usually did not have swollen ankles. The patient had her first dose of the Pfizer vaccine and was asking if ankle or leg swelling as a side effect of the vaccine. The outcome for tightness on both ankles was unknown and for rest both events was not recovered.  Information about lot/batch number has been requested.
This case was reported by a consumer via call center representative and described the occurrence of myalgia upper extremities in a 78-year-old female patient who received SHINGRIX for prophylaxis.  On 11th February 2019, the patient received the 1st dose of SHINGRIX. On 11th February 2019, less than a day after receiving SHINGRIX, the patient experienced myalgia upper extremities. The patient was treated with naproxen (Aleve). On an unknown date, the outcome of the myalgia upper extremities was not recovered/not resolved. It was unknown if the reporter considered the myalgia upper extremities to be related to SHINGRIX. Additional details were provided as follows: The patient reported that she received SHINGRIX and started having pain in the arm where she received the injection the same day she had the SHINGRIX shot and it has not improved. The patient said that it's like a muscle pain. About three days later, it even was worse. The patient said that she did not do a lot of things because of the pain. She has taken Aleve to treat it. The reporter consented to follow up.
I have had a headache since the day after I received the vaccine. Also my ears are now ringing since receiving the vaccine
body aches; headache; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body aches) and HEADACHE (headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes mellitus. Concomitant products included INSULIN for Diabetes mellitus.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (body aches) and HEADACHE (headache). At the time of the report, MYALGIA (body aches) and HEADACHE (headache) outcome was unknown.            No treatment medication were provided. Action taken for Moderna COVID-19 Vaccine was not applicable.   This case was linked to MODERNATX, INC.-MOD-2021-059899, MODERNATX, INC.-MOD-2021-059899 (E2B Linked Report).; Sender's Comments:  MODERNATX, INC.-MOD-2021-059899: MODERNATX, INC.-MOD-2021-059899:
My son suffered a seizure following MMR/Varicella vaccination approx. 7-10 days after injections. He used to repeat words/phrases and exhibit typical infant behavior. Following these vaccinations he severely regressed, lost all words/sounds he had previously gained and lost eye contact. He developed quirky behaviors ie head butting, grimacing and wincing and also OCD behaviors. Shortly following my son's 2nd Birthday, he was seen by a developmental pediatrician and diagnosed with ASD.  He is currently receiving through early intervention, including Speech and Occupational Therapy 4x/week.
Patient complained of itchy throat and having difficulty breathing. Patient said breathing felt thick. Patient denies a reaction to any other vaccines. Patient alerted observer 7 minutes into observation time. Provider alerted vaccine pod lead for benadryl and would need to be taken to ER for monitoring. Pt was wheeled down to ER immediately, no benadryl was administered. No Epi pen was given
After receiving immunizations patient ran 103 degrees to 104 degrees temperature with TYLENOL, and screamed and cried for several hours. Crying greater than three hours.
Narrative: Patient is a 74 year old M, who relates about a 10 day history of diarrhea, progressive weakness, cough and shortness of breath. He notes "everyone at home has COVID", and states he has just been miserable this past week, having no appetite, minimal oral intake and not been able to take his oral diabetic medications. Presents to agency ED and noted to be COVID positive. Clinical and radiographic evidence of COVID PNA also apparent. Admitted to COVID ward for above and related. HOSPITAL COURSE: Slow, but steady improvement in GI distress, oral tolerance and lastly pulmonary status. Unable to fully wean off oxygen, but able to reasonably ambulate with oxygen support. Discharged to home on O2 via nasal canula.
Not sure if you need this info:  NDC 58160-823-11; VIS Date 2/12/2018;  Dose 0.5 mL;  This was dose 1 of the 2 part new Shingrix vaccine.  My left arm was extremely painful which I fully expected.  However,  I had a 100 and 101 fever and chills, headache, very stiff and painful muscles and joints throughout body which impaired my walking.  I had this from about 8pm on 10/18/2019 until 1pm on 10/20/2019.  I would say that the peak / worst time of these bad reactions was from 11pm on 10/18/2018 through 8pm on 10/19/2019.  I took Advil to relieve the symptoms.  I always get a flu shot and have never experienced such adverse reactions. I am curious whether I should expect such adverse reactions for the second dose in 2-6 months.  If so, I will make sure that I have nothing scheduled.
Patient received TDaP on 6/12, within a few hours after receiving vaccine pt. noted redness to injection site and body aches. On 6/14 patient in clinic to see gynecologist. Reported left deltoid red, swollen and painful to touch. Seen by Family Practice MD, Dx: cellulitis, prescribed FLAGYL and BACTRIM DS.
Pharmacist alerted minutes after vaccination that pt was coughing and having shortness of breath.  Pharmacist observed pt and pt requested her personal EpiPen be used because she knew this was an allergic reaction,.  EpiPen was administered in right leg.  Allergic reaction drastically reduced.  Staff contacted primary care dr who advise an ER visit if  pharmacist saw fit.  Due to vaccination protocol pt agreed to be transported to ER.  Ambulance called by facility staff, 5-10min later emergency personnel arrived, pharmacist relayed events to emergency staff and pt went to ER for followup
Headache; Fatigue; This is a spontaneous report received via Optum speciality pharmacy. A contactable other healthcare professional and a non-contactable 39-year-old female consumer (patient) received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot number was not reported) via an unspecified route of administration on Aug2021 as dose number unknown, single for COVID-19 immunisation. The patient medical history was not reported. Concomitant medication included palbociclib (IBRANCE, Tablet, Strength: 125 mg) for an unspecified indication from 18Aug2021 to an unspecified stop date. The patient experienced headache and Fatigue on Aug2021. Patient reports adverse event of headache and fatigue following COVID booster shot last week. Symptoms lasted for a few days then resolved. Outcome of events was recovered on Aug2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Severe back pain and weakness. Tingling and warm sensations in legs. I've never had neurological problems with my back injury. The sensations were a new experience.
Night fever about 103 degrees starting 1w hour a after shot approx. Maybe earlier in her sleep. Flushing. Resp rate 40-50 per min. Heart rate 120. Severe body aches. Fever poorly controlled by MOTRIN. Required MOTRIN and TYLENOL around the clock to keep fever down.
Information has been received from a physician concerning a 13 month old female with AUGMENTIN allergy and no pertinent medical history reported who on 01-APR-2009, was vaccinated SC in the left upper arm with first 0.5mL dose of VARIVAX (Merck) (lot number 662459/1784X).  There was no concomitant medication.  On 11-APR-2009, the patient developed four lesions on her lower extremity.  Three of the lesions were "red bumps like bites" and one lesion "looks like a popped vesicle".  The four lesions were localized to the calf-area of the right lower leg.  No treatment was prescribed.  No lab studies were performed.  At the time of reporting, patient had not recovered from the events.  The patient sought medical attention by an office visit.  Follow up information was received from a registered nurse concerning a 13 month old female with AUGMENTIN allergy and no illness at the time of vaccination who on 01-APR-2009 in the morning, was vaccinated SC in the left arm with first dose of VARIVAX (Merck) (lot number 662459/178X).  On 10-APR-2009 at 09:31 A.M., the patient developed fever (100F) and had a red raised spot on her back and on the diaper area.  On 13-APR-2009, there was a questionable pox on her leg.  Subsequently, the patient recovered within an unspecified date. No further information is available.
33 year old female complained of scratchy throat. Onsite EMS responded vitals BP 124/78  99% O2      HR 73. 25mg Diphenhydramine given, after several minutes she felt better then went home.
aches; felt awful; This case was reported by a consumer via call center representative and described the occurrence of feeling bad in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of no adverse event (1st dose received over 2 months before and it was fine).   On an unknown date, the patient received the 2nd dose of Shingrix. On 21st December 2020, less than a month after receiving Shingrix, the patient experienced feeling bad. On 22nd December 2020, the patient experienced pain. On an unknown date, the outcome of the feeling bad and pain were not recovered/not resolved.   It was unknown if the reporter considered the feeling bad and pain to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported, however it could be 59 or 60 years old. The patient felt awful during the night and on the day of reporting after receiving 2nd booster shot of shingles. The patient wanted to know if there was anything she could take to help with thes aches. The reporter consented to follow up.
Information has been received from a medical assistant referring to a 17 year old patient of unknown gender. The patient's pertinent medical history and drug reactions/allergies were not reported. On 21-SEP-2015 the patient inadvertently received an adult dose of RECOMBIVAX HB (strength: 10 microgram, lot # reported as L014419 with expiration date 15-APR-2015; dose and route were not reported), instead of a pediatric dose. The reporter reported that this was the patients' third dose in the series and the patient had received two other pediatric doses on unspecified dates. No adverse effects were reported. Additional information has been requested.
pt started coughing, difficulty in breathing & eyelids puffy 10-15 mins p/receiving MMR & Recombivax;
This spontaneous report was received from a physician refers to a patient of unknown age and gender. The patient was vaccinated with 0.5 ml of expired dose of VARIVAX subcutaneously (lot # 667490/0784Z, expiry: 08-OCT-2012) on 08-OCT-2012. No concomitant medications were reported. No adverse effect were reported. Additional information has been requested.
pt recv vax; mom noticed swollen & redness around inject site;apap for pain; dec appetite;erythema at site; mild tenderness;hypersensitivity to dtp; possible early cellulitis;
This case was reported by a consumer and described the occurrence of periorbital swelling in a patient who received SHINGRIX for prophylaxis. On 22nd October 2018, the patient received the 2nd dose of SHINGRIX. On 22nd October 2018, less than a day after receiving SHINGRIX, the patient experienced periorbital swelling and burning sensation skin. On an unknown date, the outcome of the periorbital swelling and burning sensation skin were unknown. It was unknown if the reporter considered the periorbital swelling and burning sensation skin to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. At 8:45 am, the patient received SHINGRIX. The patient noticed in the Tuesday morning for sure or perhaps Monday morning, about the puffiness under eyes and also when the patient touched it, it felt burnt.
Cellulitis in left arm with his first dose; Tremendous painful itch; Bad rash all over body; Swelling at injection site; Sore; A spontaneous report was received from a consumer concerning himself, a 77-year-old male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced cellulitis in left arm after the first dose (cellulitis), bad rash all over body (rash), tremendous painful itch (pruritus), swelling at injection site (vaccination site swelling) and sore (vaccination site pain).  The patient's medical history was not provided. Products known to have been used by the patient, within two weeks prior to the event, included dutasteride, chlormadinone acetate and trazodone.  On 21 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Batch Number: unknown) intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On an unspecified date, the patient experienced cellulitis in left arm with his first dose. The patient had bad rash all over the body and tremendous painful itch. The patient reports swelling at injection site and sore. Treatment information included cefalexin, methylprednisolone sodium succinate, hydroxyzine and trimeolon.  On 18 Feb 2021, the patient received their second of two planned doses of mRNA-1273 (Batch Number: 013M20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection   Action taken with mRNA-1273 in response to the events was not applicable.   The outcome of the events, cellulitis in left arm after the first dose, bad rash all over body, tremendous painful itch, swelling at injection site and sore, was not recovered.; Reporter's Comments: This case concerns a 77 Y/O M who had serious unexpected cellulitis with NS unexpected painful pruritus and rash and expected vaccination site pain and vaccination site swelling.  Event onset with unknown latency after the first dose of mRNA-1273. Treated with cefalexin, methylprednisolone, hydroxyzine, trimeolon. Events ongoing. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.
Immediately following vaccination on 13 Apr 2018 at 2:30pm my arm swole up in hives and fever. A 3: diameter welt formed around the injection site.
got covid after first vaccine dose; got covid after first vaccine dose; This is a spontaneous report from a contactable consumer (reporting for neighbor) and from the same contactable consumer from a Pfizer-sponsored program . A patient of an unspecified age and gender received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number not provided), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient received the first dose of the vaccine and got COVID, on an unspecified date. The outcome of the event was unknown.      Information on the lot/batch number has been requested.
Patient received an expired Moderna Vaccine; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received an expired Moderna Vaccine) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received an expired Moderna Vaccine). On 15-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Patient received an expired Moderna Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. Treatment medications were unknown.    This case was linked to MOD-2021-237427 (Patient Link).
Vaccine administered 4/11/21. Patient developed loss of smell 4/23/21.  Has improved since that time but has not completely resolved.
Rash with hives, on trunk, ears, eyelids, arms. Took BENADRYL to stop itching. Resolved on 10/2.
PAIN AT INJECTION SITE, HEADACHE, FATIGUE, SWELLING AND REDNESS AT INJECTION SITE.
Moderately severe body aches all over the body, headache, sore throat, wooziness, feeling feverish, chills
I had extreme body fatigue and leg muscle fatigue that has lasted a total of 2 months. I experienced tingling in my legs and feet also muscle weakness in my left hand. The total body fatigue has decreased but I'm still experiencing some muscle weakness in my legs and left hand. I saw my PCP and she referred me to a neurologist. He did an exam and because my symptoms have improved somewhat and the exam was normal  he didn't recommend further testing. I'm to follow up in 2 months to see if symptoms have decreased significantly.
Swollen tongue and mouth a few minutes after injection.  Not severe.  No trouble breathing.  Lasted a few hours.
Information has been received from a nurse referring to a patient of unknown age and gender. On 06-JUL-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M033212, expiration date 13-JUL-2018; dose and route were unknown) for prophylaxis. The vaccine reconstituted with properly stored sterile diluent (lot # and expiration date were unknown). No adverse effects were reported. Data logger was involved. The vaccine was stored under -14 Celsius degree to -10 Celsius degree for 4 hours 3 minutes. Previous temperature excursion was -14 Celsius degree to -10 Celsius degree for 5 hours 13 minutes. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1707USA009387.
And, yes, I was vaccinated/ suspected vaccination failure; My case was mild but still an inconvenience; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: And, yes, I was vaccinated/ suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: My case was mild but still an inconvenience). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt date: 25-MAR-2023 This case was reported by patient via interactive digital media. The patient's case was mild but still an inconvenience since he/she was on vacation.  The patient stated that he/she was vaccinated. This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting. Follow up was not possible, as no contact details were available.
Student had 2 records in the immunization registry.  MMR on 2/4/23 was documented on different record than the vaccine given on 2/14/23.